Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | PTPRF | P10586 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951150 | 0.85 | MAPT (0.35) | TSHRMAPTSMN1; SMN2POLBGAA | |
| SCHEMBL4951358 | 0.82 | ABCC4 (0.41) | ALDH1A1TSHRMAPTNR1H4GAA | |
| SCHEMBL4953693 | 0.81 | GRIA4 (0.49) | SRD5A2KDM4E | |
| SCHEMBL4951060 | 0.81 | NPSR1 (0.44) | ALDH1A1MAPTNR1H4 | |
| SCHEMBL4953413 | 0.80 | PTGS2 (0.48) | — | |
| SCHEMBL4957941 | 0.80 | GAA (0.39) | ALDH1A1GAACYP1A2CYP2C19 | |
| SCHEMBL4945705 | 0.80 | SMN1; SMN2 (0.45) | ALDH1A1MAPTSMN1; SMN2GAACYP1A2 | |
| SCHEMBL4949814 | 0.77 | HPGD (0.45) | ALDH1A1MAPTMAPK1SMN1; SMN2GAA | |
| SCHEMBL4948474 | 0.77 | RORC (0.39) | TSHRKDM4ECYP1A2 | |
| SCHEMBL4950506 | 0.76 | PTGS2 (0.35) | ALDH1A1TSHRMAPTSRD5A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893597-B1 | AMPA RECEPTOR POTENTIATORS | LILLY CO ELI (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7393868-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142441-A1 | AMPA receptor potentiators | GABRE, GRIN1, GRIK2 | ALDH1A1 928/4885TSHR 235/4885MAPT 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.